Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Mariela Sivina"'
Autor:
Jan Burger, Ekaterina Kim, Mariela Sivina, Ghayas Issa, Philip Thompson, William G. Wierda, Alessandra Ferrajoli
Publikováno v:
HemaSphere, Vol 7, p e06532fc (2023)
Externí odkaz:
https://doaj.org/article/ce03dfa519c447a68d7c64a5cd703413
Autor:
Rong Chen, Jennifer Tsai, Philip A. Thompson, Yuling Chen, Ping Xiong, Chaomei Liu, Francis Burrows, Mariela Sivina, Jan A. Burger, Michael J. Keating, William G. Wierda, William Plunkett
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-15 (2021)
Abstract The constitutive activation of B-cell receptor (BCR) signaling, together with the overexpression of the Bcl-2 family anti-apoptotic proteins, represents two hallmarks of chronic lymphocytic leukemia (CLL) that drive leukemia cell proliferati
Externí odkaz:
https://doaj.org/article/c1c1b56b91374e5199779633b84aeb68
Autor:
Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify
Externí odkaz:
https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
Autor:
Jan A. Burger, Dan A. Landau, Amaro Taylor-Weiner, Ivana Bozic, Huidan Zhang, Kristopher Sarosiek, Lili Wang, Chip Stewart, Jean Fan, Julia Hoellenriegel, Mariela Sivina, Adrian M. Dubuc, Cameron Fraser, Yulong Han, Shuqiang Li, Kenneth J. Livak, Lihua Zou, Youzhong Wan, Sergej Konoplev, Carrie Sougnez, Jennifer R. Brown, Lynne V. Abruzzo, Scott L. Carter, Michael J. Keating, Matthew S. Davids, William G. Wierda, Kristian Cibulskis, Thorsten Zenz, Lillian Werner, Paola Dal Cin, Peter Kharchencko, Donna Neuberg, Hagop Kantarjian, Eric Lander, Stacey Gabriel, Susan O’Brien, Anthony Letai, David A. Weitz, Martin A. Nowak, Gad Getz, Catherine J. Wu
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
The BTK inhibitor ibrutinib is used to treat chronic lymphocytic leukaemia, however some patients develop resistance to the drug. Here, the authors use genomic analyses to examine the clonal evolution of 5 patients that develop resistance to ibrutini
Externí odkaz:
https://doaj.org/article/31a1991cd4d64583af26755ec24a7d52
Autor:
Simon Schliffke, Mariela Sivina, Ekaterina Kim, Lisa von Wenserski, Benjamin Thiele, Nuray Akyüz, Clemens Falker-Gieske, Donjete Statovci, Anna Oberle, Toni Thenhausen, Artus Krohn-Grimberghe, Carsten Bokemeyer, Nitin Jain, Zeev Estrov, Alessandra Ferrajoli, William Wierda, Michael Keating, Jan A. Burger, Mascha Binder
Publikováno v:
OncoImmunology, Vol 7, Iss 4 (2018)
Using next-generation immunoglobulin (IGH) sequencing and flow cytometry, we characterized the composition, diversity and dynamics of non-malignant B cells in patients undergoing treatment with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or
Externí odkaz:
https://doaj.org/article/a65454febf2744a291d53103ae94dc11
Autor:
Candida Vitale, Inhye E. Ahn, Mariela Sivina, Alessandra Ferrajoli, William G. Wierda, Zeev Estrov, Sergej N. Konoplev, Nitin Jain, Susan O’Brien, Mohammed Farooqui, Michael J. Keating, Adrian Wiestner, Jan A. Burger
Publikováno v:
Haematologica, Vol 101, Iss 6 (2016)
Externí odkaz:
https://doaj.org/article/fecdd778c8fc4241a2fcfcd7b0f0991f
Autor:
Stefania Fiorcari, Wells S Brown, Bradley W McIntyre, Zeev Estrov, Rossana Maffei, Susan O'Brien, Mariela Sivina, Julia Hoellenriegel, William G Wierda, Michael J Keating, Wei Ding, Neil E Kay, Brian J Lannutti, Roberto Marasca, Jan A Burger
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83830 (2013)
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior
Externí odkaz:
https://doaj.org/article/e562921b6e994148966ffc9a7ab695c4
Autor:
Jan A. Burger, Susan O'Brien, Hagop Kantarjian, Zeev Estrov, Alessandra Ferrajoli, Philip A. Thompson, Mariela Sivina, William G. Wierda, Michael J. Keating, Preetesh Jain
Survival outcomes for patients with del17p (n=21) treated with ibrutinibrituximab (IR) - Complex vs Non-Complex karyotype.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a9428dff50c27e68e0329e6c5778fb
https://doi.org/10.1158/1078-0432.22464008.v1
https://doi.org/10.1158/1078-0432.22464008.v1
Autor:
Jan A. Burger, Susan O'Brien, Hagop Kantarjian, Zeev Estrov, Alessandra Ferrajoli, Philip A. Thompson, Mariela Sivina, William G. Wierda, Michael J. Keating, Preetesh Jain
Changes in hematologic parameters on treatment with ibrutinib and rituximab up to 3 years.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91e71c6aabb5a2a2582012acee5c9ce
https://doi.org/10.1158/1078-0432.22464005.v1
https://doi.org/10.1158/1078-0432.22464005.v1
Autor:
Jan A. Burger, Susan O'Brien, Hagop Kantarjian, Zeev Estrov, Alessandra Ferrajoli, Philip A. Thompson, Mariela Sivina, William G. Wierda, Michael J. Keating, Preetesh Jain
Changes in absolute T cell numbers on treatment with ibrutinib and rituximab up to 3 years.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::537136e89329d4db71ec30f45f639683
https://doi.org/10.1158/1078-0432.22463999
https://doi.org/10.1158/1078-0432.22463999